Farde L, Grind M, Nilsson M I, Ogenstad S, Sedvall G
Department of Psychiatry and Psychology, Karolinska Institute, Stockholm, Sweden.
Psychopharmacology (Berl). 1988;95(2):157-61. doi: 10.1007/BF00174501.
Remoxipride, a new potential antipsychotic drug, was administered over 4 days at two dose levels, 70 and 140 mg t.i.d., to eight healthy male volunteers. Pharmacokinetics, safety, tolerability, and effect on plasma prolactin levels were evaluated. Remoxipride exhibited essentially linear pharmacokinetics. Only minor deviations in biochemical and physiological safety parameters were found. The drug was well tolerated by all subjects at the 70 mg dose level. At 140 mg akathisia appeared in seven subjects. The drug induced a rapid and transient increase in plasma prolactin concentrations at both dose levels after single doses. During steady state, a significant reduction in the prolactin response was observed as compared to after the first dose.
雷莫必利是一种新型潜在抗精神病药物,以每日三次、70毫克和140毫克两种剂量水平,对8名健康男性志愿者给药4天。评估了其药代动力学、安全性、耐受性以及对血浆催乳素水平的影响。雷莫必利表现出基本呈线性的药代动力学特征。仅发现生化和生理安全参数有轻微偏差。在70毫克剂量水平时,所有受试者对该药物耐受性良好。在140毫克剂量时,7名受试者出现了静坐不能。单次给药后,两个剂量水平的药物均引起血浆催乳素浓度迅速且短暂的升高。在稳态时,与首次给药后相比,观察到催乳素反应显著降低。